Company Overview of Celtaxsys, Inc.
Celtaxsys, Inc., a biopharmaceutical company, engages in developing and testing drug compounds for treating cancer, and inflammatory and autoimmune diseases. Its technology manipulates immune cell migration as a treatment for cancer, inflammation, and organ/tissue rejection. The company’s drug compounds are designed to block the protective mechanisms created by certain tumors to prevent attack by immune system cells. It also offers CTX-4430, an oral leukotriene A4 hydrolase inhibitor for the treatment of cystic fibrosis. Celtaxsys, Inc. was founded in 2007 and is based in Atlanta, Georgia.
311 Ferst Drive
Atlanta, GA 30332
Founded in 2007
Key Executives for Celtaxsys, Inc.
Chief Executive Officer, President and Director
Founder and Chief Financial Officer
Chairman of Medical Advisory Panel and Chief Medical Officer
Compensation as of Fiscal Year 2014.
Celtaxsys, Inc. Key Developments
Celtaxsys, Inc. Receives Regulatory Clearance to Commence the Phase 2 Trial for its Compound, CTX-4430
Apr 7 15
Celtaxsys, Inc. announced that it has received regulatory clearance to commence the phase 2 trial for its compound, CTX-4430, in patients with moderate to severe facial acne vulgaris. This approval triggers site engagement to screen and enroll appropriate patients with acne henceforth. This proof-of-concept study will assess the efficacy and safety of 100 mg CTX-4430 administered as a once daily oral dose for 12 weeks. Effects on inflammatory lesion counts will serve as the primary efficacy outcome. Effects on non-inflammatory lesion counts as well as an Investigator's Global Assessment (the physician's overall assessment of the patient's disease) will also be studied. This phase 2 acne vulgaris study will be conducted at approximately 10 sites in Australia and New Zealand with Dr. Lynda J Spelman, MBBS FACD as the Principal Investigator.
U.S. Food and Drug Administration Grants Orphan Drug Designation to Celtaxsys, Inc.'s Once Daily, Oral Leukotriene A4 Hydrolase Inhibitor
Feb 3 15
Celtaxsys, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) to its once daily, oral leukotriene A4 hydrolase inhibitor (CTX-4430) for the treatment of cystic fibrosis (CF). The U.S. orphan designation complements the orphan designation for use of CTX-4430 in the treatment of CF in the European Union granted late last year by the European Medicines Agency. Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 patients in the US. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon approval, as well as certain financial incentives that can help support its future development.
Celtaxsys Announces Sanjeev Ahuja as Chief Medical Officer
Nov 6 14
Celtaxsys, Inc. announced the appointment of Sanjeev Ahuja, MD, MBA, FACP as Chief Medical Officer, effective November 1, 2014. Sanjeev most recently Chief Medical Officer at On Target Laboratories.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|